SCHEMBL6468008

SCHEMBL6468008

CON(C)C(=O)[C@H](CCc1ccccc1)NC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
JAK3 P52333 1/20 0.46
BTK Q06187 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 3/20 0.43
TSHR P16473 2/20 0.42
USP2 O75604 1/20 0.42
CNR2 P34972 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
GAA P10253 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27215383 1.00 SMN1; SMN2 (0.48) SMN1; SMN2JAK3BTKMEN1KMT2A
SCHEMBL14572893 0.89 JAK3 (0.44) SMN1; SMN2JAK3BTKMEN1KMT2A
SCHEMBL8098620 0.86 CTSL (0.55) MEN1KMT2AALDH1A1CTSSCTSK
SCHEMBL1701577 0.86 CTSL (0.55) MEN1KMT2AALDH1A1CTSSCTSK
SCHEMBL6191522 0.86 MMP9 (0.55) ALDH1A1CYP2C9CYP2C19CTSSCTSK
SCHEMBL6193090 0.86 MMP9 (0.55) ALDH1A1CYP2C9CYP2C19CTSSCTSK
SCHEMBL1250617 0.86 MMP9 (0.55) ALDH1A1CYP2C9CYP2C19CTSSCTSK
SCHEMBL24414243 0.85 MMP9 (0.54) SMN1; SMN2MEN1KMT2AHTTHPGD
SCHEMBL3720453 0.85 JAK3 (0.64) JAK3BTKCTSSCTSK
SCHEMBL3763894 0.85 JAK3 (0.64) JAK3BTKCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150396-A1 INHIBITORS OF CYSTEINE PROTEASES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-05-09 US disclosed
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP disclosed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US disclosed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150396-A1 INHIBITORS OF CYSTEINE PROTEASES CTRL, SERPINB1, PRSS1 SMN1; SMN2 3825/4885JAK3 3635/4885BTK 3472/4885
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ SMN1; SMN2 4034/4885JAK3 2680/4885BTK 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.